Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.2M Buy
5,702
+630
+12% +$135K ﹤0.01% 1301
2026
Q1
$1.11M Sell
5,072
-906
-15% -$222K 0.01% 1238
2025
Q4
$1.52M Sell
5,978
-762
-11% -$191K 0.01% 992
2025
Q3
$1.67M Buy
6,740
+1,167
+21% +$279K 0.01% 837
2025
Q2
$1.34M Buy
5,573
+1,838
+49% +$428K 0.01% 850
2025
Q1
$825K Buy
3,735
+345
+10% +$75.9K 0.01% 900
2024
Q4
$690K Buy
3,390
+1,720
+103% +$377K 0.01% 922
2024
Q3
$406K Buy
+1,670
New +$391K 0.01% 957

Other funds holding STE

&Partners's STE Position: Q2 2026 in Review

&Partners increased its Steris (STE) stake by 12% in Q2 2026, buying an estimated $135K and bringing the position to 5,702 shares worth $1.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1301.

&Partners first reported a position in STE in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.67M in Q3 2025. 835 funds tracked by Wall St. Rank hold STE as of Q2 2026.

  • &Partners held 5,702 shares of Steris worth $1.2M as of Q2 2026.
  • &Partners bought 630 Steris shares in Q2 2026, an estimated $135K.
  • Steris made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #1301 holding.
  • &Partners first reported a position in Steris in Q3 2024 and has held it in 8 quarters since.
  • &Partners's Steris position peaked at $1.67M in Q3 2025.
  • 835 funds tracked by Wall St. Rank held Steris as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.